Skip to main content
Premium Trial:

Request an Annual Quote

GenoSpace, PathGroup, Thomson Reuters Collaborate on Personalized Medicine for Oncology

NEW YORK (GenomeWeb News) – GenoSpace, PathGroup, and Thomson Reuters' IP & Science business today announced an initiative aimed at personalized medicine in oncology.

The partners will combine their resources, technologies, and expertise to integrate PathGroup's SmartGenomics next generation DNA sequencing and cytogenomic array with traditional pathology assays, enabling genetic profiling that may lead to greater insights into disease and patient treatment options, they said.

PathGroup's anatomic, clinical, and molecular pathology services are being integrated with Thomson Reuters' information about genes, variants, and therapeutic implications, and then "overlaid" with GenoSpace's analytical and information integration capabilities "to place this diverse data into context."

Individualized reports will soon be sent to oncologists that provide information for the best therapies for their patients.

PathGroup recently opened its new facility dedicated to molecular testing and will begin offering new service offerings in next-generation sequencing and cytogenomic arrays for the genetic profiling of cancer patients.

"The GenoSpace FullView and GenoSpace for Clinical platforms integrate the vast pathology resources available at PathGroup with sequence and array data and information, tying in the extensive knowledgebase available through Thomson Reuters, and deliver concise, relevant and actionable reports to oncologists in a format that they find useful in making treatment decisions," GenoSpace CEO John Quackenbush said in a statement. "By bringing together the complementary strengths of each company, we will be able to deliver a market-leading solution in personalized genomic medicine."

Financial and other terms of the deal were not disclosed.